Alzheimer's wonder drugs aren't yet delivering on their promise. American researchers have come up with a brand new idea, a ...

According to Alnylam’s Tim Mooney, mivelsiran’s endurance is due to stabilizing tweaks the scientists made to the siRNA ...

Authorization is based on results from the Phase 3 CARTITUDE-4 (MMY3002) study, which showed treatment with CARVYKTI® reduced the risk of disease progression or death by 74 per cent compared to ...

Stock recommendation on SIGA Technologies affected by mpox outbreak response, diversifying into mAbs for orthopoxviruses, remains speculative buy.

Nature is adept at designing proteins. Scientists are even better. But artificial intelligence holds the promise of improving ...

Nature is pretty good at designing proteins. Scientists are even better. But artificial intelligence holds the promise of improving proteins many ...

The biggest use for hydroxychloroquine is to treat or prevent malaria, a serious and potentially deadly parasitic infection ...

The subtleties of antibody-target interaction can guide the development of better malaria treatments and vaccines.

As part of an international collaboration, Fred Hutch scientists provided structural information that helped reveal how two ...

Pharmanovia has signed a licensing agreement with Lindis Biotech to commercialise catumaxomab, a new trifunctional ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...